Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
Optimizing the Management of Endocrine-Resistant HR-Positive Metastatic Breast Cancer
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Th...
Understanding the Concerns and Challenges of Patients With HR-Positive/HER2-Negative EBC: Expert ...
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Tri...
Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Gu...
European Society for Medical Oncology (ESMO)
ASCO 2023 Expert Report in HR positive, HER2 negative breast cancer by Catherine Harper-Wynne
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
Recent Updates in HR-Positive/HER2-Negative Early Breast Cancer: A Deep Dive Into Understanding t...
HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Th...
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-nega...
Inside the Issue: Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Tri...
Evolving Perspectives on HR-Positive Metastatic Breast Cancer: Current Understanding and New Insi...
Global Healthcare Activities Academy
Recent Advances in the Treatment of HR Positive, HER2 Negative Metastatic Breast Cancer
Integrating Antibody-Drug Conjugates into the Management of HR-Positive and Triple-Negative Metas...
Why Do I Need Adjuvant Therapy? Communicating the Risks for HR-Positive, HER2-Negative EBC at Hig...
Optimizing the Management of Endocrine-Resistant HR-Positive Metastatic Breast Cancer: Video Lecture
The Role of Biomarkers in HR-Positive/HER2-Negative Early Breast Cancer: From Clinical Analysis t...
HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit
Clinical Cases in HR-Positive, HER2-Negative Early Breast Cancer: Applying the Latest Evidence
Adjuvant ET +/- 1 year of everolimus in patients with high-risk HR-positive, HER2-negative BC
Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer
